Compare NYAX & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | HRMY |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2022 | 2020 |
| Metric | NYAX | HRMY |
|---|---|---|
| Price | $67.29 | $33.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $49.50 | $44.11 |
| AVG Volume (30 Days) | 10.9K | ★ 741.9K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $30.66 | $19.75 |
| Revenue Next Year | $21.70 | $12.88 |
| P/E Ratio | $89.78 | ★ $61.44 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $39.17 | $25.52 |
| 52 Week High | $76.86 | $40.87 |
| Indicator | NYAX | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 41.71 |
| Support Level | $62.44 | $33.07 |
| Resistance Level | $68.79 | $35.47 |
| Average True Range (ATR) | 1.98 | 1.36 |
| MACD | -0.04 | -0.55 |
| Stochastic Oscillator | 45.81 | 17.17 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It unifies payments, operations management, and customer engagement tools into a powerful, adaptable platform for modern commerce. It provides solutions that empower businesses to enhance customer experience, accept cashless payments, and manage their operations with a robust Internet of Things (IoT) software platform, helping achieve long-term growth. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.